Novo Nordisk A/S (NYSE:NVO) has collaborated with IndiaMART to remove unauthorized listings of its weight-loss drug Wegovy in India. IndiaMART took action after discussions with Novo Nordisk, who is the sole patent holder of semaglutide, the active ingredient in Wegovy and diabetes medication Ozempic. The company's legal team in India is working to establish a framework to notify and remove counterfeit listings to curb illegal sales. Despite the challenges in tracing illegal sellers, Novo Nordisk regularly monitors and engages with platforms to prevent unauthorized sales. IndiaMART has been listed on a U.S. government agency's 'Notorious Markets' list for 2022, indicating ongoing issues with counterfeit goods. NVO shares saw a 1.46% increase to $100.43.